Concert Pharmaceuticals Inc (NASDAQ:CNCE) COO Nancy Stuart Sells 10,295 Shares

Concert Pharmaceuticals Inc (NASDAQ:CNCE) COO Nancy Stuart sold 10,295 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $11.34, for a total transaction of $116,745.30. Following the completion of the sale, the chief operating officer now directly owns 167,924 shares of the company’s stock, valued at $1,904,258.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of CNCE traded down $0.31 during mid-day trading on Thursday, reaching $11.21. The company had a trading volume of 88,600 shares, compared to its average volume of 127,655. The company has a debt-to-equity ratio of 0.10, a current ratio of 11.87 and a quick ratio of 11.87. The company has a market capitalization of $332.41 million, a P/E ratio of -3.66 and a beta of 0.93. Concert Pharmaceuticals Inc has a twelve month low of $5.36 and a twelve month high of $13.09. The company’s 50-day moving average is $9.52 and its 200-day moving average is $9.57.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.04. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.02 million. Concert Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 97,236.70%. As a group, equities analysts expect that Concert Pharmaceuticals Inc will post -2.89 EPS for the current fiscal year.

Several research analysts have recently issued reports on CNCE shares. Mizuho restated a “buy” rating and set a $18.00 price objective on shares of Concert Pharmaceuticals in a report on Monday, June 1st. Jefferies Financial Group assumed coverage on Concert Pharmaceuticals in a research note on Monday, March 30th. They set a “buy” rating and a $23.00 price target on the stock. Zacks Investment Research downgraded Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Stifel Nicolaus cut Concert Pharmaceuticals to a “hold” rating and boosted their price objective for the company from $8.00 to $11.00 in a research report on Thursday, February 27th. Finally, ValuEngine lowered Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 27th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $18.43.

Institutional investors and hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new stake in shares of Concert Pharmaceuticals during the 1st quarter worth about $16,429,000. Bank of America Corp DE grew its stake in Concert Pharmaceuticals by 22.8% during the fourth quarter. Bank of America Corp DE now owns 1,790,166 shares of the biotechnology company’s stock worth $16,514,000 after buying an additional 332,585 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Concert Pharmaceuticals by 16.4% during the first quarter. BlackRock Inc. now owns 1,753,460 shares of the biotechnology company’s stock worth $15,500,000 after buying an additional 246,806 shares in the last quarter. Sphera Funds Management LTD. raised its stake in shares of Concert Pharmaceuticals by 623.6% in the first quarter. Sphera Funds Management LTD. now owns 1,013,039 shares of the biotechnology company’s stock valued at $8,955,000 after acquiring an additional 873,039 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Concert Pharmaceuticals by 2.7% in the 4th quarter. Renaissance Technologies LLC now owns 634,400 shares of the biotechnology company’s stock worth $5,852,000 after acquiring an additional 16,610 shares in the last quarter. 66.66% of the stock is currently owned by institutional investors and hedge funds.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

See Also: Hedge Funds Explained

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.